Pipeline
Our pipeline focuses on novel small molecule kinase inhibitors targeting malignant cells both directly and through modulation of the tumor microenvironment. Verastem Oncology programs include:
PI3K Delta Gamma Inhibitor
FAK Inhibitor
These studies are investigating treatments or outcomes that have not received approval from a Health Authority. There is no guarantee that the outcome of these studies will result in approval.
Investigator Sponsored Trials (IST)
The mission of Verastem Oncology Investigator Sponsored Trial (IST) program is to advance the medical and scientific knowledge pertaining to our product candidates and disease states of interest. We welcome collaboration with researchers and sponsoring institutions.
For additional details regarding our IST program or to submit a research request, please complete and submit the below form via email to verastem-IST@verastem.com.